Metastatic Ovarian Cancer-Pipeline Review, H2 2015

Metastatic Ovarian Cancer-Pipeline Review, H2 2015


  • Products Id :- GMDHC7259IDB
  • |
  • Pages: 78
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Metastatic Ovarian Cancer-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Metastatic Ovarian Cancer-Pipeline Review, H2 2015', provides an overview of the Metastatic Ovarian Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Metastatic Ovarian Cancer Overview 7

Therapeutics Development 8

Pipeline Products for Metastatic Ovarian Cancer-Overview 8

Pipeline Products for Metastatic Ovarian Cancer-Comparative Analysis 9

Metastatic Ovarian Cancer-Therapeutics under Development by Companies 10

Metastatic Ovarian Cancer-Therapeutics under Investigation by Universities/Institutes 11

Metastatic Ovarian Cancer-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Metastatic Ovarian Cancer-Products under Development by Companies 14

Metastatic Ovarian Cancer-Products under Investigation by Universities/Institutes 15

Metastatic Ovarian Cancer-Companies Involved in Therapeutics Development 16

Cellceutix Corporation 16

Eisai Co., Ltd. 17

F. Hoffmann-La Roche Ltd. 18

Immune Design Corp. 19

Millennium Pharmaceuticals, Inc. 20

Natco Pharma Limited 21

Northwest Biotherapeutics, Inc. 22

Sumitomo Dainippon Pharma Co., Ltd. 23

VG Life Sciences, Inc. 24

Metastatic Ovarian Cancer-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Combination Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

DCVax-Direct-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

DCVax-L-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Drugs for Metastatic Ovarian Cancer-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

E-7449-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

emactuzumab-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

G-305-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

hydroxychloroquine + sorafenib tosylate-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

KM-3174-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

LV-305-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

NRCAN-019-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

orteronel-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

SM-276001-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Vaccine for Oncology-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Metastatic Ovarian Cancer-Recent Pipeline Updates 55

Metastatic Ovarian Cancer-Dormant Projects 74

Metastatic Ovarian Cancer-Discontinued Products 75

Metastatic Ovarian Cancer-Product Development Milestones 76

Featured News & Press Releases 76

Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent 76

Appendix 77

Methodology 77

Coverage 77

Secondary Research 77

Primary Research 77

Expert Panel Validation 77

Contact Us 77

Disclaimer 78

List of Tables

Number of Products under Development for Metastatic Ovarian Cancer, H2 2015 8

Number of Products under Development for Metastatic Ovarian Cancer-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Products under Development by Companies, H2 2015 14

Products under Investigation by Universities/Institutes, H2 2015 15

Metastatic Ovarian Cancer-Pipeline by Cellceutix Corporation, H2 2015 16

Metastatic Ovarian Cancer-Pipeline by Eisai Co., Ltd., H2 2015 17

Metastatic Ovarian Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 18

Metastatic Ovarian Cancer-Pipeline by Immune Design Corp., H2 2015 19

Metastatic Ovarian Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 20

Metastatic Ovarian Cancer-Pipeline by Natco Pharma Limited, H2 2015 21

Metastatic Ovarian Cancer-Pipeline by Northwest Biotherapeutics, Inc., H2 2015 22

Metastatic Ovarian Cancer-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 23

Metastatic Ovarian Cancer-Pipeline by VG Life Sciences, Inc., H2 2015 24

Assessment by Monotherapy Products, H2 2015 25

Assessment by Combination Products, H2 2015 26

Number of Products by Stage and Target, H2 2015 28

Number of Products by Stage and Mechanism of Action, H2 2015 30

Number of Products by Stage and Route of Administration, H2 2015 32

Number of Products by Stage and Molecule Type, H2 2015 34

Metastatic Ovarian Cancer Therapeutics-Recent Pipeline Updates, H2 2015 55

Metastatic Ovarian Cancer-Dormant Projects, H2 2015 74

Metastatic Ovarian Cancer-Discontinued Products, H2 2015 75

List of Figures

Number of Products under Development for Metastatic Ovarian Cancer, H2 2015 8

Number of Products under Development for Metastatic Ovarian Cancer-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 12

Assessment by Monotherapy Products, H2 2015 25

Number of Products by Top 10 Targets, H2 2015 27

Number of Products by Stage and Top 10 Targets, H2 2015 27

Number of Products by Top 10 Mechanism of Actions, H2 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 29

Number of Products by Top 10 Routes of Administration, H2 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 31

Number of Products by Top 10 Molecule Types, H2 2015 33

Number of Products by Stage and Top 10 Molecule Types, H2 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Cellceutix Corporation

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Immune Design Corp.

Millennium Pharmaceuticals, Inc.

Natco Pharma Limited

Northwest Biotherapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

VG Life Sciences, Inc.

Metastatic Ovarian Cancer Therapeutic Products under Development, Key Players in Metastatic Ovarian Cancer Therapeutics, Metastatic Ovarian Cancer Pipeline Overview, Metastatic Ovarian Cancer Pipeline, Metastatic Ovarian Cancer Pipeline Assessment

select a license

Single User License
USD 2000 INR 128720
Site License
USD 4000 INR 257440
Corporate User License
USD 6000 INR 386160

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com